medigraphic.com
Instituto Nacional de Salud Pública

2012, Number 1

<< Back Next >>

salud publica mex 2012; 54 (1)

Cost-effectiveness analysis of the use of palivizumab in the prophylaxis of preterm patients in Mexico

Salinas-Escudero G, Martínez-Valverde S, Reyes-López A, Garduño-Espinosa J, Muñoz-Hernández O, Granados-García V, Rely K

Language: English
References: 48
Page: 47-59
PDF size: 132.30 Kb.


ABSTRACT

Objective. The study evaluated the incremental cost-effectiveness ratio (ICER) of the prophylaxis of palivizumab, for the reduction of complications associated to the respiratory syncytial virus in preterm patients in Mexico. Material and Methods. A decision tree was developed in preterm groups [‹29 and 29-32 weeks of gestational age (wGA)], by using epidemiological and cost local data; the effectiveness was obtained with a systematic review. Patients were evaluated according to their life expectancy. Mexican Health System perspective was used. Effectiveness measures employed were LYG and QALYs. The costs are reported in USD 2009. Results. ICERs per LYG resulted on values of USD $25,029 and USD $29,637 for ‹29 wGA and 29-32 wGA respectively, whereas ICERs per QALYs obtained in the model accounted for USD $17,532 and USD $20,760. Conclusions. Palivizumab prophylaxis for preterm newborn patients ≤32 weeks of age resulted in a cost-effective alternative.


REFERENCES

  1. Meissner HC, Welliver RC, Chartrand SA, Law BJ, Weisman LE, Dorkin HL, et al. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr Infect Dis J 1999;18(3):223-231.

  2. Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodríguez WJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 1993;329(21): 1524-1530.

  3. Carbonell-Estrany X, Quero J, and the IRIS Study Group. Tasas de hospitalización por infección por virus respiratorio sincitial en prematuros nacidos en dos estaciones consecutivas. Pediatr Infect Dis J 2001;20(9):874-879.

  4. Piedimonte G. The association between respiratory syncytial virus infection and reactive airway disease. Respir Med 2002; 96 Suppl B:S25-S29.

  5. Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005;171(2):137-141.

  6. Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbersgsson F, Bjarnason R, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 2010; 65(12):1045-1052. doi:10.1136/thx.2009.121582.

  7. Cardenas S, Auais A, Piedimonte G. Palivizumab in the prophylaxis of respiratory syncytial virus infection. Expert Rev Anti Infect Ther 2005;3(5):719-726.

  8. Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 2007;151(1):34-42, e1.

  9. Puddu M, Fanos V. Respiratory syncytial virus infection and recurrent wheezing: what next? J Chemother 2007;19 Suppl 2:8-11.

  10. Bont L, Steijn M, Van Aalderen WM, Kimpen JL. Impact of whezzing after respiratory syncytial virus infection on healthrelated quality of life. Pediatr Infect Dis J 2004;23(5):414-417.

  11. Greenough A, Alexander J, Burgess S, Bytham J, Chetcuti PA, Hagan J, et al. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection. Arch Dis Child 2004;89(7): 673-678.

  12. World Health Organization (WHO). Respiratory syncytial virus and parainfluenza viruses. [Update September 2009]. [Accessed 2009 November] Available at: http://www.who.int/vaccine_research/diseases/ari/en/index2.html

  13. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999;282(15):1440-1446.

  14. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001;344(25):1917-1928.

  15. Henrickson KJ, Hoover S, Kehl KS, Hua W. National disease burden of respiratory viruses detected in children by polymerase chain reaction. Pediatr Infect Dis J 2004;23(1 Suppl):S11-S118.

  16. Garenne M, Ronsmans C, Campbell H. The magnitude of mortality from acute respiratory infections in children under 5 years in developing countries. World Health Stat Q 1992; 45(2-3):180-191.

  17. ElHassan NO, Sorbero ME, Hall CB, Stevens TP, Dick AW. Costeffectiveness Analysis of Palivizumab in Premature Infants Without Chronic Lung Disease. Arch Pediatr Adolesc Med 2006;160(10):1070-1076.

  18. Chirico G, Ravasio R, Sbarigia U. Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants. Italian J Pediatr 2009;35(1):4.

  19. Yount LE, Mahle WT. Economic Analysis of Palivizumab in Infants With Congenital Heart Disease Pediatrics 2004;114(6);1606-11.

  20. Nuijten MJ, Wittenberg W. Cost effectiveness of palivizumab in Spain: an analysis using observational data. Eur J Health Econ 2010;11(1):105-115.

  21. Secretaría de Gobernación. Anexo Estadístico Tercer Informe de Gobierno. Felipe Calderón Hinojosa. 2009. Pag 270. [Accessed 2009 November 6]. Available at: http://www.informe.gob.mx/anexo_estadistico/pdf/2_3.pdf.

  22. Instituto Nacional de Estadística y Geografía. XII Censo General de Población y Vivienda 2000. México: INEGI, 2000.

  23. Instituto Nacional de Estadística y Geografía. II Conteo de Población y Vivienda 2005. México: INEGI, 2006.

  24. Instituto Mexicano del Seguro Social (IMSS). Estadísticas Médicas DATA MART. Asistencia Infantil. Peso y Edad Gestacional Enero-Junio 2009. [Accessed 2009 September 15]. Available at: http://www.imss.gob.mx/dpm/dis/Tabla.aspx?ID=SCRS04_0020_09&OPC=opc04&SRV=M00-1

  25. Consejo Nacional de Población (CONAPO). Indicadores demográficos básicos 1990-2030.[ Accessed 2009 November]. Available at: http://www.conapo.gob.mx/index.php?option=com_content&view=article&id=125&Itemid=193

  26. Secretaría de Gobernación. Anexo Estadístico Tercer informe de Gobierno. Felipe Calderón Hinojosa. 2009. Pag 59. [Accessed 2009 October 15] Available at: http://www.informe.gob.mx/anexo_estadistico/pdf/1_4.pdf.

  27. Fenton TR. A new growth chart for preterm babies: Babson and Benda’s chart updated with recent data and a new format. BMC Pedriatr 2003;16; 3:13

  28. National Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000). USA. [Accessed 2009 October]: Available at: http://www.cdc.gov/growthcharts

  29. Wright AL, Taussig LM, Ray CG, Harrison HR, Holberg CJ. The Tucson Children’s Respiratory Study. II. Lower respiratory tract illness in the first year of life. Am J Epidemiol 1989; 129(6):1232-1246.

  30. Darville T, Yamauchi T. Respiratory syncytial virus. Pediatr Rev 1998; 19(2):55-61

  31. Dubois B, Ray G. Viral infections of the lower respiratory tract. Pediatric Respiratory Medicine. China: Taussig-Landau, 1999; 573-579.

  32. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J, and IRIS Study Group. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 2003;22(9):823-827.

  33. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, et al. Cardiac Synagis Study Group: Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143(4):532-540.

  34. The Impact-RSV Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102(3):531-537.

  35. Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sánchez PJ, Steichen J, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J 1998;17(2):110-115.

  36. Checchia PA, Nalysnyk L, Fernandes A, Mahadevia P, Xu Y, Fahrbach K, et al. Mortality and Morbidity Among High-Risk Preterm Infants Receiving Palivizumab Prophylaxis: A Systematic Review and Meta- Analysis. Pediatric Crit Care Med. 2011;12(5):580-588.

  37. Ravasio R, Lucioni C, Chirico G. Costo-efficacia di palivizumab versus non profilassi nella prevenzione delle infezioni da VRS nei bambini pretermine, a diversa età gestazionale. PharmacoEconomics – Italian Research Articles 2006; 8(2):105-117.

  38. Instituto Mexicano del Seguro Social. Secretaria General de Aviso: Costos unitarios de la atención médica. Diario Oficial de la Federación. Martes 9 de marzo de 2004. Primera Sección.

  39. Instituto Mexicano del Seguro Social (IMSS). Portal de Transparencia. IMSS va a comprar, IMSS compró. Periodo Enero-Diciembre 2008: [Accessed 2009 November]. Available at: http://transparencia.imss.gob.mx/trnsp/ncompro.aspx?c=1

  40. Banco de México. Inflación. [Accessed 2009 November 19]. Available at: http://www.banxico.org.mx/portal-inflacion/index.html

  41. Briggs AH, Goeree R, Blackhouse G, O’Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002;22(4): 290-308.

  42. Wegner S, Jacobson-Vann J, Liu G, Byrns P, Cypra C, Campbell W, et al. Direct Cost Analyses of Palivizumab Treatment in a Cohort of At-Risk Children: Evidence From the North Carolina Medicaid Program. Pediatrics 2004;114(6):1612-1619.

  43. Martínez ZI, Bahena ME, Jurado LS, Hosking JE. Costo directo de la atención por crisis aguda de asma en el servicio de urgencias pediátricas. Rev Alergia Mex 2004; 51(4):134-138.

  44. Banco de México. Mercado cambiario. [Accessed 2009 November 19]. Available at: http://www.banxico.org.mx/portal-mercado-cambiario/index.html

  45. World Health Organization. World Health Report 2000. Health Systems: Improving Performance. Geneva Switzerland. [Accessed 2009 October]. Available at: http://www.who.int/whr/2000/en/whr00_en.pdf

  46. Jonsson B. Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics 2004; 22(suppl 4):5-10.

  47. Instituto Nacional de Estadística y Geografía (INEGI). Sistema de Cuentas Nacionales. [Accessed 2009 November]. Available at: http://dgcnesyp.inegi.org.mx/cgi-win/bdiecoy.exe/572?s=est&c=12546

  48. Consejo Nacional de Población (CONAPO). Indicadores demográficos básicos 1990-2030. [Accessed 2009 October] Available at: http://www.conapo.gob.mx/index.php?option=com_content&view=article&id=125&Itemid=193.




2020     |     www.medigraphic.com